Download PDF
Thorac Cardiovasc Surg 2022; 70(08): 677-683
DOI: 10.1055/s-0041-1728714
Review Article

Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

Katharina Martini
1   University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, Zurich, ZH, Switzerland
2   University of Zurich, Faculty of Medicine Zurich, ZH, Switzerland
,
Thomas Frauenfelder
1   University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, Zurich, ZH, Switzerland
2   University of Zurich, Faculty of Medicine Zurich, ZH, Switzerland
› Author Affiliations
› Further Information
   Permissions and Reprints All articles of this category

Abstract

Background The purpose of this article is to describe the various imaging techniques involved in detection, staging, and preoperative planning in malignant pleural mesothelioma (MPM) focusing on new imaging modalities.

Methods For this purpose, first a brief summary of the etiology of MPM is given. Second, not only the commonly known, but also novel imaging modalities used in MPM will be discussed.

Results A wide range of imaging methods, from conventional chest radiography, through computed tomography and hybrid imaging to radiomics and artificial intelligence, can be used to evaluate MPM.

Conclusion Nowadays multimodality imaging is considered the cornerstone in MPM diagnosis and staging.

Keywords

imaging - mesothelioma - pleural disease - tumor


Publication History

Received: 28 January 2021

Accepted: 08 March 2021

Article published online:
01 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27 (12) 2081-2090
    CrossrefPubMedGoogle Scholar
  • 2 Falaschi F, Romei C, Fiorini S. et al. Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?—a systematic review about the use of screening programs in a population of asbestos exposed workers. J Thorac Dis 2017; 10( (Suppl. 02) S262-S268
    PubMedGoogle Scholar
  • 3 Nickell Jr LT, Lichtenberger III JP, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics 2014; 34 (06) 1692-1706
    CrossrefPubMedGoogle Scholar
  • 4 Gill RR, Tsao AS, Kindler HL. et al. Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol 2019; 14 (10) 1718-1731
    CrossrefPubMedGoogle Scholar
  • 5 Sinha S, Swift AJ, Kamil MA. et al. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol 2020; 75 (06) 423-432
    CrossrefPubMedGoogle Scholar
  • 6 Dynes MC, White EM, Fry WA, Ghahremani GG. Imaging manifestations of pleural tumors. Radiographics 1992; 12 (06) 1191-1201
    CrossrefPubMedGoogle Scholar
  • 7 Craighead JE. Current pathogenetic concepts of diffuse malignant mesothelioma. Hum Pathol 1987; 18 (06) 544-557
    CrossrefPubMedGoogle Scholar
  • 8 Wang ZJ, Reddy GP, Gotway MB. et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24 (01) 105-119
    CrossrefPubMedGoogle Scholar
  • 9 Bonomo L, Feragalli B, Sacco R, Merlino B, Storto ML. Malignant pleural disease. Eur J Radiol 2000; 34 (02) 98-118
    CrossrefPubMedGoogle Scholar
  • 10 Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol 2015; 10 (09) 1240-1242
    CrossrefPubMedGoogle Scholar
  • 11 Miller A, Widman SA, Miller JA, Manowitz A, Markowitz SB. Comparison of x-ray films and low-dose computed tomographic scans: demonstration of asbestos-related changes in 2760 nuclear weapons workers screened for lung cancer. J Occup Environ Med 2013; 55 (07) 741-745
    CrossrefPubMedGoogle Scholar
  • 12 Ricciardi S, Cardillo G, Zirafa CC. et al. Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis 2018; 10 (Suppl. 02) S285-S292
    CrossrefPubMedGoogle Scholar
  • 13 Alexander E, Clark RA, Colley DP, Mitchell SE. CT of malignant pleural mesothelioma. AJR Am J Roentgenol 1981; 137 (02) 287-291
    CrossrefPubMedGoogle Scholar
  • 14 Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ. From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Radiographics 1996; 16 (03) 613-644
    CrossrefPubMedGoogle Scholar
  • 15 Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990; 154 (03) 487-492
    CrossrefPubMedGoogle Scholar
  • 16 Corson N, Sensakovic WF, Straus C, Starkey A, Armato III SG. Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans. Med Phys 2011; 38 (02) 942-947
    CrossrefPubMedGoogle Scholar
  • 17 Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172 (04) 1039-1047
    CrossrefPubMedGoogle Scholar
  • 18 Armato III SG, Blyth KG, Keating JJ. et al. Imaging in pleural mesothelioma: a review of the 13th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2016; 101: 48-58
    CrossrefPubMedGoogle Scholar
  • 19 Lococo F, Rena O, Torricelli F. et al. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results. Interact Cardiovasc Thorac Surg 2020; 30 (04) 593-596
    CrossrefPubMedGoogle Scholar
  • 20 Marom EM, Erasmus JJ, Pass HI, Patz Jr EF. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29 (01) 26-35
    CrossrefPubMedGoogle Scholar
  • 21 Frauenfelder T, Kestenholz P, Hunziker R. et al. Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma. J Comput Assist Tomogr 2015; 39 (02) 160-165
    CrossrefPubMedGoogle Scholar
  • 22 Patel AM, Berger I, Wileyto EP. et al. The value of delayed phase enhanced imaging in malignant pleural mesothelioma. J Thorac Dis 2017; 9 (08) 2344-2349
    CrossrefPubMedGoogle Scholar
  • 23 Patel A, Roshkovan L, McNulty S. et al. Delayed-phase enhancement for evaluation of malignant pleural mesothelioma on computed tomography: a prospective cohort study. Clin Lung Cancer 2020; S1525-7304 (20) 30184-4
    PubMedGoogle Scholar
  • 24 Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16 (01) 145-152
    CrossrefPubMedGoogle Scholar
  • 25 Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113 (03) 723-731
    CrossrefPubMedGoogle Scholar
  • 26 Murphy DJ, Gill RR. Volumetric assessment in malignant pleural mesothelioma. Ann Transl Med 2017; 5 (11) 241
    CrossrefPubMedGoogle Scholar
  • 27 Frauenfelder T, Tutic M, Weder W. et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?. Eur Respir J 2011; 38 (01) 162-168
    CrossrefPubMedGoogle Scholar
  • 28 Proto C, Signorelli D, Mallone S. et al. The prognostic role of TNM staging compared with tumor volume and number of pleural sites in malignant pleural mesothelioma. Clin Lung Cancer 2019; 20 (06) e652-e660
    CrossrefPubMedGoogle Scholar
  • 29 Plathow C, Klopp M, Thieke C. et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 2008; 18 (08) 1635-1643
    CrossrefPubMedGoogle Scholar
  • 30 Chen M, Helm E, Joshi N, Gleeson F, Brady M. Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method. Int J CARS 2017; 12 (04) 529-538
    CrossrefPubMedGoogle Scholar
  • 31 Appenzeller P, Mader C, Huellner MW. et al. PET/CT versus body coil PET/MRI: how low can you go?. Insights Imaging 2013; 4 (04) 481-490
    CrossrefPubMedGoogle Scholar
  • 32 Antoch G, Vogt FM, Freudenberg LS. et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290 (24) 3199-3206
    CrossrefPubMedGoogle Scholar
  • 33 Huellner MW, Appenzeller P, Kuhn FP. et al. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. Radiology 2014; 273 (03) 859-869
    CrossrefPubMedGoogle Scholar
  • 34 Martini K, Meier A, Opitz I. et al. Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. Lung Cancer 2016; 94: 40-45
    CrossrefPubMedGoogle Scholar
  • 35 Yildirim H, Metintas M, Entok E. et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol 2009; 4 (12) 1480-1484
    CrossrefPubMedGoogle Scholar
  • 36 Lim JH, Choi JY, Im Y. et al. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. PLoS One 2020; 15 (02) e0229299
    CrossrefPubMedGoogle Scholar
  • 37 Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010; 67 (03) 311-317
    CrossrefPubMedGoogle Scholar
  • 38 Zucali PA, Lopci E, Ceresoli GL. et al. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Med 2017; 6 (10) 2287-2296
    CrossrefPubMedGoogle Scholar
  • 39 Choudhury A. Predicting cancer using supervised machine learning: Mesothelioma. Technol Health Care 2021; 29 (01) 45-58
    CrossrefPubMedGoogle Scholar
  • 40 Weyn B, Van De Wouwer G, Koprowski M. et al. Value of morphometry, texture analysis, densitometry, and histometry in the differential diagnosis and prognosis of malignant mesothelioma. J Pathol 1999; 189 (04) 581-589
    CrossrefPubMedGoogle Scholar
  • 41 Pena E, Ojiaku M, Inacio JR. et al. Can CT and MR shape and textural features differentiate benign versus malignant pleural lesions?. Acad Radiol 2017; 24 (10) 1277-1287
    CrossrefPubMedGoogle Scholar
  • 42 Pavic M, Bogowicz M, Kraft J. et al. FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Res 2020; 10 (01) 81
    CrossrefPubMedGoogle Scholar
  • 43 Rusch VW. From the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108 (04) 1122-1128
    CrossrefPubMedGoogle Scholar
  • 44 Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 2018; 7 (05) 543-549
    CrossrefPubMedGoogle Scholar
  • 45 Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15 (02) 257-260
    CrossrefPubMedGoogle Scholar
  • 46 Scherpereel A, Opitz I, Berghmans T. et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55 (06) 1900953
    CrossrefPubMedGoogle Scholar
  • 47 Falaschi F, Boraschi P, Musante F. et al. The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study [in Italian]. Radiol Med (Torino) 1992; 84 (1–2): 43-47
    PubMedGoogle Scholar
  • 48 Ollier M, Chamoux A, Naughton G, Pereira B, Dutheil F. Chest CT scan screening for lung cancer in asbestos occupational exposure: a systematic review and meta-analysis. Chest 2014; 145 (06) 1339-1346
    CrossrefPubMedGoogle Scholar
  • 49 Prezzi D, Khan A, Goh V. Perfusion CT imaging of treatment response in oncology. Eur J Radiol 2015; 84 (12) 2380-2385
    CrossrefPubMedGoogle Scholar
  • 50 Sudarski S, Shi J, Schmid-Bindert G. et al. Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy. J Thorac Oncol 2015; 10 (01) 164-171
    CrossrefPubMedGoogle Scholar
  • 51 Gudmundsson E, Labby Z, Straus CM. et al. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol 2019; 29 (02) 682-688
    CrossrefPubMedGoogle Scholar
  • 52 Lennartz S, Le Blanc M, Zopfs D. et al. Dual-energy CT-derived iodine maps: use in assessing pleural carcinomatosis. Radiology 2019; 290 (03) 796-804
    CrossrefPubMedGoogle Scholar
  • 53 Willemink MJ, Persson M, Pourmorteza A, Pelc NJ, Fleischmann D. Photon-counting CT: technical principles and clinical prospects. Radiology 2018; 289 (02) 293-312
    CrossrefPubMedGoogle Scholar